Fundamental Analysis of TONIX PHARMACEUTICALS HOLDIN(NASDAQ:TNXP) stock

Fundamental Rating

Taking everything into account, TNXP scores 2 out of 10 in our fundamental rating. TNXP was compared to 629 industry peers in the Biotechnology industry. TNXP scores bad on very profitability, while its financial health is fine. Not spectacular, but in line with the averages. TNXP is valued expensive and it does not seem to be growing.

Note: TNXP has only limited data available, so a full analysis was not possible, which makes the total rating unfair.

Profitability

Profitability Rating

VS Industry

Valuation

Valuation Rating

When comparing the current price to the book value of TNXP, it is valued rather cheaply. It is trading at 0.10 times its book value.

Compared to an average industry price book ratio of 1.82, TNXP is valued rather cheaply. On top of this, TNXP is cheaper than 99% of the companies listed in the same industry.

TNXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year TNXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

VS Industry

Price/Book (0.1) VS Industry: 99% outperformed.

255.75

0.09

Growth

Growth Rating

TNXP is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 23.84% yearly.

TNXP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -59.93%.

	5Y	3Y	1Y	1Y	2Y	3Y	5Y
	Past			Future
EPS	N/A	N/A	-59.93%	77.07%	36.64%	23.84%	N/A
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Health

Health Rating

A Current Ratio of 6.40 indicates that TNXP has no problem at all paying its short term obligations.

TNXP has a Quick Ratio of 6.40. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.

TNXP has a Current Ratio comparable to the industry average, which is at 5.40.

The Quick Ratio is in line with the industry averages, which is at 5.24.

When comparing the Debt to Equity Ratio of TNXP to the average industry Debt to Equity Ratio of 0.00, TNXP required more debt to finance its operations than its industry peers.
We won't put much weight on the industry comparison as TNXP has a very low Debt to Equity (0.00).

Based on the Altman-Z score of -5.01, we must say that TNXP is in the distress zone and has some risk of bankruptcy.

When comparing the Altman-Z score of TNXP to the average industry Altman-Z score of -1.15, TNXP is less financially healthy than its industry peers.

VS Industry

Debt/Equity (0) VS Industry: 39% outperformed.

22.69

0.00

Quick Ratio (6.4) VS Industry: 57% outperformed.

0.02

87.97

Current Ratio (6.4) VS Industry: 56% outperformed.

0.04

87.97

Altman-Z (-5.01) VS Industry: 31% outperformed.

-289.03

312.45

Dividend

Dividend Rating

No dividends for TNXP!.

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (5/26/2023, 7:00:02 PM)

After market: 1.6501 -0.02 (-1.19%)

1.67

-0.03 (-1.76%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-08 2023-05-08/bmo

Earnings (Next)08-07 2023-08-07/bmo

Inst Owners73.29%

Inst Owner Change-18.48%

Ins Owners0.03%

Ins Owner Change0%

Market Cap17.27M

Analysts82.5

Price Target41.44 (2381.44%)

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)15.52%

Min EPS beat(2)-5.11%

Max EPS beat(2)36.16%

EPS beat(4)3

Avg EPS beat(4)20.49%

Min EPS beat(4)-5.11%

Max EPS beat(4)36.16%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

PT rev (1m)541.45%

PT rev (3m)541.45%

EPS NQ rev (1m)-320.26%

EPS NQ rev (3m)-155.24%

EPS NY rev (1m)0%

EPS NY rev (3m)37.27%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.1
P/tB	0.1
EV/EBITDA	N/A

EPS(TTM)-12.28

EYN/A

EPS(NY)-1.41

Fwd EYN/A

FCF(TTM)-12.73

FCFYN/A

OCF(TTM)-9.66

OCFYN/A

SpSN/A

BVpS16

TBVpS16

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM	N/A
GM	N/A

ROICexgc(3y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc(3y)N/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-ScoreN/A

Asset TurnoverN/A

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	1523.24%
Profit Quality	N/A
Current Ratio	6.4
Quick Ratio	6.4
Altman-Z	-5.01

F-ScoreN/A

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)34330%

Cap/Depr(5y)20615.3%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

Growth

EPS 1Y-59.93%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-103.12%

EPS Next Y77.07%

EPS Next 2Y36.64%

EPS Next 3Y23.84%

EPS Next 5YN/A

Revenue growth 1YN/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-21.98%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-89.78%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-65.7%

OCF growth 3YN/A

OCF growth 5YN/A

Fundamental Stock Screener Links

TONIX PHARMACEUTICALS HOLDIN (TNXP)

Fundamental Rating

Profitability

Profitability Rating

VS Industry

Valuation

Valuation Rating

VS Industry

Growth

Growth Rating

Health

Health Rating

VS Industry

Dividend

Dividend Rating

Fundamental Stock Screener

Best Fundamental Competitors Stock Screener

Best Valuation Competitors Stock Screener

Best Dividend Competitors Stock Screener